Published in Breast Cancer Res on April 08, 2005
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med (2007) 2.90
HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res (2006) 2.74
Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res (2007) 1.78
Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol (2009) 1.67
Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer. Breast Cancer Res (2009) 1.20
Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. Cancer Res (2010) 1.17
Protein kinase A activation confers resistance to trastuzumab in human breast cancer cell lines. Clin Cancer Res (2009) 1.10
HER-2/neu diagnostics in breast cancer. Breast Cancer Res (2007) 1.04
Integrin-associated CD151 drives ErbB2-evoked mammary tumor onset and metastasis. Neoplasia (2012) 0.99
Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens. Curr Pharmacogenomics Person Med (2009) 0.99
Increased Circulating Level of the Survival Factor GP88 (Progranulin) in the Serum of Breast Cancer Patients When Compared to Healthy Subjects. Breast Cancer (Auckl) (2011) 0.97
Metabolic characterization of triple negative breast cancer. BMC Cancer (2014) 0.94
Label-free, all-electrical, in situ human epidermal growth receptor 2 detection. Rev Sci Instrum (2008) 0.92
Impact of Serum HER2 Levels on Survival and Its Correlation with Clinicopathological Parameters in Women with Breast Cancer. J Breast Cancer (2012) 0.85
Lapatinib induces p27(Kip1)-dependent G₁ arrest through both transcriptional and post-translational mechanisms. Cell Cycle (2013) 0.85
Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status. Oncotarget (2016) 0.84
Monitoring serum HER2 levels in breast cancer patients. Springerplus (2015) 0.81
Circulating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients? Biomark Cancer (2013) 0.80
Serum HER2/ECD value in stage I and II early breast cancer: need of a lower cut-off? Wien Klin Wochenschr (2011) 0.79
Serum HER2 levels determined by two methods in patients with metastatic breast cancer. Int J Clin Oncol (2011) 0.78
Predicting brain metastases of breast cancer based on serum S100B and serum HER2. Oncol Lett (2013) 0.76
Outcome prediction values of soluble human epidermal growth factor receptor-2 extracellular domain in metastatic breast cancer. Int J Clin Exp Pathol (2014) 0.76
HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer. Oncoscience (2015) 0.76
Label-free Growth Receptor-2 Detection and Dissociation Constant Assessment in Diluted Human Serum Using a Longitudinal Extension Mode of a Piezoelectric Microcantilever Sensor. Sens Actuators B Chem (2011) 0.75
Herbal tonic does not inhibit estrogen receptor negative mammary tumor development in a transgenic mouse model. J Complement Integr Med (2011) 0.75
HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis. Oncotarget (2016) 0.75
Reproducible cancer biomarker discovery in SELDI-TOF MS using different pre-processing algorithms. PLoS One (2011) 0.75
A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression. Breast Cancer Res Treat (2016) 0.75
A Tri-part Protein Complementation System Using Antibody-Small Peptide Fusions Enables Homogeneous Immunoassays. Sci Rep (2017) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 13.81
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol (1999) 11.78
Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature (1986) 6.67
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol (1996) 4.99
Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol (2000) 3.56
2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2001) 3.25
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 2.75
Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol (2002) 2.70
Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res (2004) 1.97
HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst (2000) 1.85
Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol (2003) 1.72
HER-2-targeted therapy: lessons learned and future directions. Clin Cancer Res (2003) 1.42
The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene (1997) 1.35
HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res (1998) 1.20
Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol (2001) 1.15
Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer. Anticancer Res (2001) 1.13
The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens. Annu Rev Med (1996) 1.07
In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells. Cancer Chemother Pharmacol (2003) 1.01
ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic breast cancer. Int J Biol Markers (2004) 0.96
Is circulating HER-2 more than just a tumor marker? Clin Cancer Res (2001) 0.93
Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma. Cancer (2004) 0.86
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol (2007) 14.29
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res (2007) 6.59
Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol (2009) 3.90
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol (2006) 2.85
Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell (2002) 2.67
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. J Clin Oncol (2008) 2.28
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol (2007) 1.93
Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist (2008) 1.85
Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance. Oncotarget (2012) 1.67
Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol (2003) 1.67
Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Cancer (2008) 1.63
Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc (2006) 1.57
Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol (2008) 1.55
HER2-positive breast cancer: beyond trastuzumab. Oncology (Williston Park) (2010) 1.52
Translational crossroads for biomarkers. Clin Cancer Res (2005) 1.38
Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol Cancer Res (2012) 1.33
Shaping the future of biomarker research in breast cancer to ensure clinical relevance. Nat Rev Cancer (2007) 1.31
Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat (2007) 1.30
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol (2007) 1.25
Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Res Treat (2005) 1.20
Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. Breast Cancer Res (2008) 1.15
FOXO1A is a target for HER2-overexpressing breast tumors. Cancer Res (2010) 1.11
Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. Breast Cancer Res Treat (2006) 1.11
Prevalence and significance of vitamin D deficiency and insufficiency among apparently healthy adults. Clin Biochem (2010) 1.10
RIN1 is a breast tumor suppressor gene. Cancer Res (2007) 1.05
Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA. BJU Int (2004) 1.04
A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther (2002) 1.03
Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol Oncol (2007) 1.03
A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects. J Cancer Res Clin Oncol (2009) 1.01
Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer (2008) 1.00
Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study. Clin Chem (2004) 1.00
A human ovarian carcinoma murine xenograft model useful for preclinical trials. Gynecol Oncol (2002) 0.98
Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer (2007) 0.97
Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression. J Urol (2005) 0.94
Fifth-generation digital immunoassay for prostate-specific antigen by single molecule array technology. Clin Chem (2011) 0.94
Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4. J Ovarian Res (2013) 0.91
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. J Clin Oncol (2009) 0.91
A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy. J Am Geriatr Soc (2006) 0.88
Influence of imprecision on ROC curve analysis for cardiac markers. Clin Chem (2006) 0.88
Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study. Anticancer Drugs (2007) 0.86
A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clin Cancer Res (2011) 0.86
Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol (2002) 0.85
Anion gap among patients of multiple myeloma and normal individuals. Clin Biochem (2006) 0.85
Comparison of high performance liquid chromatography, radio immunoassay and electrochemiluminescence immunoassay for quantification of serum 25 hydroxy vitamin D. Clin Biochem (2011) 0.83
A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer. Breast Cancer Res Treat (2013) 0.83
Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis. Urology (2002) 0.83
A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma. Breast Cancer Res Treat (2008) 0.81
Comparision between bed side testing of blood glucose by glucometer vs centralized testing in a tertiary care hospital. J Ayub Med Coll Abbottabad (2008) 0.81
B-type natriuretic peptide versus amino terminal pro-B type natriuretic peptide: selecting the optimal heart failure marker in patients with impaired kidney function. BMC Nephrol (2013) 0.81
Prostate-specific antigen velocity accurately predicts response to salvage radiotherapy in men with biochemical relapse after radical prostatectomy. Urology (2005) 0.79
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer. Clin Cancer Res (2004) 0.79
Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500. Cancer Gene Ther (2002) 0.79
Maitake beta-glucan promotes recovery of leukocytes and myeloid cell function in peripheral blood from paclitaxel hematotoxicity. Cancer Immunol Immunother (2010) 0.79
Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors. Anticancer Drugs (2006) 0.79
Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible. Clin Breast Cancer (2008) 0.79
Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening. Urology (2002) 0.78
Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer. Urology (2003) 0.78
Bone health status of premenopausal healthy adult females in Pakistani females. Arch Osteoporos (2012) 0.78
A new prognostic model for testicular germ cell tumours. APMIS (2003) 0.77
Association between ductal fluid proteomic expression profiles and the presence of lymph node metastases in women with breast cancer. Surgery (2004) 0.77
Anabolic therapies for osteoporosis. N Engl J Med (2007) 0.76
Epothilones in breast cancer: current status and future directions. Expert Rev Anticancer Ther (2008) 0.76
Oral iron chelation therapy with deferiprone in patients with Thalassemia Major. J Pak Med Assoc (2009) 0.75
Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity. Anticancer Drugs (2009) 0.75
Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. Urology (2002) 0.75
Evaluation of the clinical performance of equimolar- and skewed-response total prostate-specific antigen assays versus complexed and free PSA assays and their ratios in discriminating between benign prostatic hyperplasia and prostate cancer. Clin Chim Acta (2002) 0.75
Error identification in a high-volume clinical chemistry laboratory: Five-year experience. Scand J Clin Lab Invest (2015) 0.75
Diagnostic efficacy of 0, 30, 45, 60, 90 and 120 min growth hormone samples in insulin tolerance test: utility of growth hormone measurement at different time-points and a cost-effective analysis. Scand J Clin Lab Invest (2009) 0.75
Pattern of drugs of abuse identified in chemical samples. J Coll Physicians Surg Pak (2010) 0.75
Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen? Urology (2002) 0.75